Molecular Dynamics Simulations in Drug Discovery

With the advancement in information technology, the dynamic understanding of drug binding to a specific target protein can be achieved using molecular dynamics simulation (MD) approach. This enhancement has scaled up the simulation capability from femto- to millisecond simulation time which is closer to what happens to molecular interaction in vivo . The dynamic understanding of drug behaviour can reasonably lead to targeted and effective design in the drug discovery process. In this review, we highlight and discuss the contribution of MD simulations in battling one of the oldest and modern-day diseases, tuberculosis. Discussion on the role of MD simulation in understanding the behaviour of selected drug targets, as well as in elucidating the interactions between the drug targets and their potential inhibitors are covered in this review.

[1]  K. Mdluli,et al.  Tuberculosis drug discovery and emerging targets , 2014, Annals of the New York Academy of Sciences.

[2]  C. E. Barry,et al.  The genetics and biochemistry of isoniazid resistance in mycobacterium tuberculosis. , 2000, Microbes and infection.

[3]  K. Forbes,et al.  Molecular Evidence for Heterogeneity of the Multiple-Drug-Resistant Mycobacterium tuberculosisPopulation in Scotland (1990 to 1997) , 1999, Journal of Clinical Microbiology.

[4]  A. Caflisch,et al.  Molecular dynamics in drug design. , 2015, European journal of medicinal chemistry.

[5]  V. Uversky,et al.  Role of solvent properties of aqueous media in macromolecular crowding effects , 2016, Journal of biomolecular structure & dynamics.

[6]  Fouad S. Husseini,et al.  Examining the role of protein structural dynamics in drug resistance in Mycobacterium tuberculosis† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc03336b , 2017, Chemical science.

[7]  A. Cavalli,et al.  Role of Molecular Dynamics and Related Methods in Drug Discovery. , 2016, Journal of medicinal chemistry.

[8]  Sanjay Kumar,et al.  Ursolic acid and carvacrol may be potential inhibitors of dormancy protein small heat shock protein16.3 of Mycobacterium tuberculosis , 2018, Journal of biomolecular structure & dynamics.

[9]  F. Seixas,et al.  Mutations in catalase-peroxidase KatG from isoniazid resistant Mycobacterium tuberculosis clinical isolates: insights from molecular dynamics simulations , 2017, Journal of Molecular Modeling.

[10]  Aditi Singh,et al.  Role of pncA gene mutations W68R and W68G in pyrazinamide resistance , 2018, Journal of cellular biochemistry.

[11]  Nanda Ghoshal,et al.  3D-QSAR studies and shape based virtual screening for identification of novel hits to inhibit MbtA in Mycobacterium tuberculosis , 2015, Journal of biomolecular structure & dynamics.

[12]  Soumi Sengupta,et al.  Structural insight into Mycobacterium tuberculosis maltosyl transferase inhibitors: pharmacophore-based virtual screening, docking, and molecular dynamics simulations , 2015, Journal of biomolecular structure & dynamics.

[13]  G. Bai,et al.  Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. , 1995, The Journal of infectious diseases.

[14]  G. Bai,et al.  Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis , 1995, Antimicrobial agents and chemotherapy.

[15]  T. Weisbrod,et al.  NADH Dehydrogenase Defects Confer Isoniazid Resistance and Conditional Lethality in Mycobacterium smegmatis , 1998, Journal of bacteriology.

[16]  Calvin Yu-Chian Chen,et al.  The Inhibition of Folylpolyglutamate Synthetase (folC) in the Prevention of Drug Resistance in Mycobacterium tuberculosis by Traditional Chinese Medicine , 2014, BioMed research international.

[17]  K. Drlica,et al.  Role of Superoxide in Catalase-Peroxidase-Mediated Isoniazid Action against Mycobacteria , 1998, Antimicrobial Agents and Chemotherapy.

[18]  M. Berney,et al.  Bactericidal mode of action of bedaquiline. , 2015, The Journal of antimicrobial chemotherapy.

[19]  Mary Jackson,et al.  Cell Wall Core Galactofuran Synthesis Is Essential for Growth of Mycobacteria , 2001, Journal of bacteriology.

[20]  Jacob D. Durrant,et al.  Molecular dynamics simulations and drug discovery , 2011, BMC Biology.

[21]  M. A. Islam,et al.  Identification of promising DNA GyrB inhibitors for Tuberculosis using pharmacophore‐based virtual screening, molecular docking and molecular dynamics studies , 2017, Chemical biology & drug design.

[22]  I. H. Lim,et al.  Contribution of kasA Analysis to Detection of Isoniazid-Resistant Mycobacterium tuberculosisin Singapore , 1999, Antimicrobial Agents and Chemotherapy.

[23]  P. Yogeeswari,et al.  Structure-based design of diverse inhibitors of Mycobacterium tuberculosis N-acetylglucosamine-1-phosphate uridyltransferase: combined molecular docking, dynamic simulation, and biological activity , 2015, Journal of Molecular Modeling.

[24]  G. Lamichhane,et al.  A comparative modeling and molecular docking study on Mycobacterium tuberculosis targets involved in peptidoglycan biosynthesis , 2016, Journal of biomolecular structure & dynamics.

[25]  An-Suei Yang,et al.  Predicting Ligand Binding Sites on Protein Surfaces by 3-Dimensional Probability Density Distributions of Interacting Atoms , 2016, PloS one.

[26]  Rohit Shukla,et al.  Distant Phe345 mutation compromises the stability and activity of Mycobacterium tuberculosis isocitrate lyase by modulating its structural flexibility , 2017, Scientific Reports.

[27]  Mohammad Imran Siddiqi,et al.  Identification of Novel Inhibitors of Mycobacterium tuberculosis PknG Using Pharmacophore Based Virtual Screening, Docking, Molecular Dynamics Simulation, and Their Biological Evaluation , 2015, J. Chem. Inf. Model..

[28]  U. Leartsakulpanich,et al.  Rational design of InhA inhibitors in the class of diphenyl ether derivatives as potential anti-tubercular agents using molecular dynamics simulations , 2014, SAR and QSAR in environmental research.

[29]  Emidio Capriotti,et al.  Bioinformatics and variability in drug response: a protein structural perspective , 2012, Journal of The Royal Society Interface.

[30]  L. Koymans,et al.  A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910 , 2007, Proteins.

[31]  David E. Shaw,et al.  The future of molecular dynamics simulations in drug discovery , 2011, Journal of Computer-Aided Molecular Design.

[32]  James C. Sacchettini,et al.  Inactivation of the inhA-Encoded Fatty Acid Synthase II (FASII) Enoyl-Acyl Carrier Protein Reductase Induces Accumulation of the FASI End Products and Cell Lysis of Mycobacterium smegmatis , 2000, Journal of bacteriology.

[33]  Suresh Kumar Chitta,et al.  Comprehensive structural and functional characterization of Mycobacterium tuberculosis UDP-NAG enolpyruvyl transferase (Mtb-MurA) and prediction of its accurate binding affinities with inhibitors , 2011, Interdisciplinary Sciences: Computational Life Sciences.

[34]  E. Parker,et al.  Quaternary structure is an essential component that contributes to the sophisticated allosteric regulation mechanism in a key enzyme from Mycobacterium tuberculosis , 2017, PloS one.

[35]  Stefania Girotto,et al.  Reduced Affinity for Isoniazid in the S315T Mutant ofMycobacterium tuberculosis KatG Is a Key Factor in Antibiotic Resistance* , 2003, The Journal of Biological Chemistry.

[36]  Tanya Parish,et al.  The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. , 2002, Microbiology.

[37]  Thomas Scior,et al.  Elucidating Isoniazid Resistance Using Molecular Modeling , 2009, J. Chem. Inf. Model..

[38]  Rohit Shukla,et al.  Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase , 2018, Journal of biomolecular structure & dynamics.

[39]  P. Bharatam,et al.  Shape-based virtual screening, docking, and molecular dynamics simulations to identify Mtb-ASADH inhibitors , 2015, Journal of biomolecular structure & dynamics.

[40]  F. Kramer,et al.  Genotypic Analysis of Mycobacterium tuberculosis in Two Distinct Populations Using Molecular Beacons: Implications for Rapid Susceptibility Testing , 2000, Antimicrobial Agents and Chemotherapy.

[41]  Rohit Shukla,et al.  Alterations in conformational topology and interaction dynamics caused by L418A mutation leads to activity loss of Mycobacterium tuberculosis isocitrate lyase. , 2017, Biochemical and biophysical research communications.

[42]  Hao Fan,et al.  Refinement of homology‐based protein structures by molecular dynamics simulation techniques , 2004, Protein science : a publication of the Protein Society.

[43]  D. Sriram,et al.  Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations , 2018, Journal of biomolecular structure & dynamics.

[44]  C. Colombo,et al.  A Second, Druggable Binding Site in UDP‐Galactopyranose Mutase from Mycobacterium tuberculosis? , 2016, Chembiochem : a European journal of chemical biology.

[45]  S. Genheden,et al.  The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.

[46]  Sameer Hassan,et al.  Insights into RpoB clinical mutants in mediating rifampicin resistance in Mycobacterium tuberculosis. , 2016, Journal of molecular graphics & modelling.

[47]  S. Cole,et al.  Missense mutations in the catalase‐peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis , 1995, Molecular microbiology.

[48]  Yushir R. Maharaj,et al.  Identification of Novel Gyrase B Inhibitors as Potential Anti‐TB drugs: Homology Modelling, Hybrid Virtual Screening and Molecular Dynamics Simulations , 2013, Chemical biology & drug design.

[49]  D. Ferguson,et al.  Quantitative three dimensional structure linear interaction energy model of 5'-O-[N-(salicyl)sulfamoyl]adenosine and the aryl acid adenylating enzyme MbtA. , 2008, Journal of medicinal chemistry.

[50]  L. Hanna,et al.  Analysis of interactions of clinical mutants of catalase-peroxidase (KatG) responsible for isoniazid resistance in Mycobacterium tuberculosis with derivatives of isoniazid. , 2017, Journal of global antimicrobial resistance.

[51]  S. Sinha,et al.  Mechanistic Principles Behind Molecular Mechanism of Rifampicin Resistance in Mutant RNA Polymerase Beta Subunit of Mycobacterium tuberculosis , 2017, Journal of cellular biochemistry.

[52]  Vanaja Kumar,et al.  Andrographolide: A potent antituberculosis compound that targets Aminoglycoside 2'-N-acetyltransferase in Mycobacterium tuberculosis. , 2015, Journal of molecular graphics & modelling.

[53]  P. Kiepiela,et al.  Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. , 2000, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[54]  A. Telenti,et al.  Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level , 1997, Journal of clinical microbiology.

[55]  A. Nargotra,et al.  Discovery of new $${\varvec{Mycobacterium~tuberculosis}}$$Mycobacteriumtuberculosis proteasome inhibitors using a knowledge-based computational screening approach , 2015, Molecular Diversity.

[56]  G. Besra,et al.  A new interpretation of the structure of the mycolyl-arabinogalactan complex of Mycobacterium tuberculosis as revealed through characterization of oligoglycosylalditol fragments by fast-atom bombardment mass spectrometry and 1H nuclear magnetic resonance spectroscopy. , 1995, Biochemistry.

[57]  Helen L Birch,et al.  The Mycobacterial Cell Wall--Peptidoglycan and Arabinogalactan. , 2015, Cold Spring Harbor perspectives in medicine.

[58]  Giacomo Fiorin,et al.  Binding of the antitubercular pro-drug isoniazid in the heme access channel of catalase-peroxidase (KatG). A combined structural and metadynamics investigation. , 2014, The journal of physical chemistry. B.

[59]  Active Site Flexibility of Mycobacterium tuberculosis Isocitrate Lyase in Dimer Form. , 2017, Journal of chemical information and modeling.

[60]  W L Jorgensen,et al.  Rusting of the lock and key model for protein-ligand binding. , 1991, Science.

[61]  N. Ghoshal,et al.  Integration of ligand and structure based approaches for identification of novel MbtI inhibitors in Mycobacterium tuberculosis and molecular dynamics simulation studies. , 2016, Journal of molecular graphics & modelling.

[62]  Jianzhuang Yao,et al.  Understanding the Catalytic Mechanism and the Nature of the Transition State of an Attractive Drug-Target Enzyme (Shikimate Kinase) by Quantum Mechanical/Molecular Mechanical (QM/MM) Studies. , 2017, Chemistry.

[63]  M. McNeil,et al.  Galactofuranose biosynthesis in Escherichia coli K-12: identification and cloning of UDP-galactopyranose mutase , 1996, Journal of bacteriology.

[64]  G. Riccardi,et al.  The katE gene, which encodes the catalase HPII of Mycobacterium avium , 1996, Molecular microbiology.

[65]  J. Aznar,et al.  Use of Real-Time PCR and Fluorimetry for Rapid Detection of Rifampin and Isoniazid Resistance-Associated Mutations in Mycobacterium tuberculosis , 2000, Journal of Clinical Microbiology.

[66]  A. Garcia,et al.  V67L Mutation Fills an Internal Cavity To Stabilize RecA Mtu Intein. , 2017, Biochemistry.

[67]  M. Naveen,et al.  Probing ligand binding modes of Mycobacterium tuberculosis MurC ligase by molecular modeling, dynamics simulation and docking , 2010, Journal of molecular modeling.

[68]  D. Sloan,et al.  The role of delamanid in the treatment of drug-resistant tuberculosis , 2015, Therapeutics and clinical risk management.

[69]  U. Deva Priyakumar,et al.  Dynamics Based Pharmacophore Models for Screening Potential Inhibitors of Mycobacterial Cyclopropane Synthase , 2015, J. Chem. Inf. Model..

[70]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[71]  P. Ortiz de Montellano,et al.  Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. , 2007, Bioorganic & medicinal chemistry.

[72]  A. Telenti Genetics of drug resistant tuberculosis , 1998 .

[73]  C. G. Mohan,et al.  Homology modeling, molecular dynamics and inhibitor binding study on MurD ligase of Mycobacterium tuberculosis , 2012, Interdisciplinary Sciences: Computational Life Sciences.

[74]  K. Herrmann,et al.  THE SHIKIMATE PATHWAY. , 1999, Annual review of plant physiology and plant molecular biology.

[75]  M. Tamoi,et al.  Crystal structure of the catalase–peroxidase KatG W78F mutant from Synechococcus elongatus PCC7942 in complex with the antitubercular pro‐drug isoniazid , 2015, FEBS letters.

[76]  S. Irle,et al.  Elucidating the structural basis of diphenyl ether derivatives as highly potent enoyl-ACP reductase inhibitors through molecular dynamics simulations and 3D-QSAR study , 2014, Journal of Molecular Modeling.

[77]  Amit Nargotra,et al.  Benzothiazole Derivative as a Novel Mycobacterium tuberculosis Shikimate Kinase Inhibitor: Identification and Elucidation of Its Allosteric Mode of Inhibition , 2016, J. Chem. Inf. Model..

[78]  A. Singh,et al.  Insight into the structural flexibility and function of Mycobacterium tuberculosis isocitrate lyase. , 2015, Biochimie.

[79]  M. Halim,et al.  Multiple receptor conformers based molecular docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP reductase (InhA). , 2017, Journal of molecular graphics & modelling.

[80]  Ying Zhang,et al.  New drug candidates and therapeutic targets for tuberculosis therapy. , 2006, Drug discovery today.

[81]  Karina S Machado,et al.  Effect of the explicit flexibility of the InhA enzyme from Mycobacterium tuberculosis in molecular docking simulations , 2011, BMC Genomics.

[82]  M. Tamoi,et al.  The crystal structure of isoniazid‐bound KatG catalase‐peroxidase from Synechococcus elongatus PCC7942 , 2015, The FEBS journal.

[83]  Luiz Augusto Basso,et al.  Combining molecular dynamics and docking simulations of the cytidine deaminase from Mycobacterium tuberculosis H37Rv , 2012, Journal of Molecular Modeling.

[84]  Gaurava Srivastava,et al.  Molecular investigation of active binding site of isoniazid (INH) and insight into resistance mechanism of S315T-MtKatG in Mycobacterium tuberculosis. , 2017, Tuberculosis.

[85]  Richard E. Lee,et al.  New agents for the treatment of drug-resistant Mycobacterium tuberculosis. , 2016, Advanced drug delivery reviews.

[86]  O. N. de Souza,et al.  Observed crowding effects on Mycobacterium tuberculosis 2-trans-enoyl-ACP (CoA) reductase enzyme activity are not due to excluded volume only , 2017, Scientific Reports.

[87]  R. Vishwakarma,et al.  Computationally Guided Identification of Novel Mycobacterium tuberculosis GlmU Inhibitory Leads, Their Optimization, and in Vitro Validation. , 2016, ACS combinatorial science.

[88]  R. Sarma,et al.  Cell wall permeability assisted virtual screening to identify potential direct InhA inhibitors of Mycobacterium tuberculosis and their biological evaluation , 2018, Journal of biomolecular structure & dynamics.